Novo Nordisk, Roche, Amgen Score Top Marks in 2011 CenterWatch Global Site Survey

BOSTON--(BUSINESS WIRE)-- A new CenterWatch survey released today shows drug sponsors have continued to improve their relationships with investigative sites by focusing on strategies to improve site quality and performance.

The 2011 CenterWatch Global Investigative Site Survey marks the first time CenterWatch has asked sites around the world simultaneously, including in the U.S. and Europe, to rank pharmaceutical and biotechnology companies. In total, 1,205 clinical research site professionals evaluated pharmaceutical and biotechnology companies across 29 individual relationship attributes. The survey, conducted during February and March, asked investigative sites to rate only those companies for which they had conducted clinical trials during the past two years. Detailed survey results are published in the June issue of The CenterWatch Monthly newsletter.

Six sponsor companies—Novo Nordisk, Roche, Amgen, Bayer, Abbott Laboratories and AstraZeneca— received top marks in this year’s survey. Novo Nordisk and Roche dominated the results, each ranking in the top three in 17 of the 29 relationship attributes measured. Three additional sponsors—Eli Lilly, Takeda and Novartis—also received high scores from investigative sites. Rankings are based on a combination of two measures: an overall rating based on combined “excellent/good” scores, and the frequency with which they placed among the top-three rated sponsors across the 29 individual attributes. Most of the top 20 largest pharmaceutical and biotechnology companies received ratings from a large enough sample of sites.

Novo Nordisk received the highest “excellent” score for overall relationship quality at 61%. The Denmark-based pharmaceutical company reached the top spot by creating partnerships with its investigative sites, improving communication with site staff and focusing on making sure everyone involved in the clinical trial process understood the importance of his or her role in drug development.

“We’re very pleased to be publishing the results of our first truly global survey of investigative sites,” said Joan Chambers, COO of CenterWatch. “With more than half of all FDA-regulated clinical trials now conducted abroad, it’s extremely important to have this global perspective. Given the critical role that sponsor-site relationships play, sponsor companies take this feedback from their sites very seriously.”

Pharmaceutical and biotechnology companies interested in receiving a comprehensive report on their company-specific results of the 2011 CenterWatch Global Site Survey of Sponsors can contact Steve Zisson, at (617) 948-5142 or [email protected]. Custom reports can provide company-specific results compared with past survey findings and industry benchmarks.

About CenterWatch

Founded in 1994, CenterWatch is a trusted source and global destination of clinical trials information for both professionals and patients. CenterWatch provides a wide variety of information services including grant leads for investigative sites, business development leads for contract service providers, career opportunity postings, listings of clinical trials actively seeking patients, advertising and promotional opportunities and proprietary business analysis and data about the global clinical trials industry. Visit www.centerwatch.com.



CONTACT:

CenterWatch
Cheryl Appel Rosenfeld, 617-948-5172
Editor-in-Chief
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Medical Devices  Pharmaceutical  Professional Services  Finance  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.